Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.

Trial Profile

Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Nov 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 16 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top